Assignee
GENETHON
FR·34 granted patents·52 pending applications·79 citations·filing 2003–2025
Top patents by PatentIndex Score
86 records- 0193US10166272B2Efficient systemic treatment of dystrophic muscle pathologiesGENETHON·Filed 2015·Granted Jan 1, 2019·16 cites·12 claims
- 0289US11421211B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Granted Aug 23, 2022·4 cites·9 claims
- 0389US10752898B2Effective gene therapy tools for dystrophin exon 53 skippingGENETHON·Filed 2016·Granted Aug 25, 2020·34 cites·15 claims
- 0488US10786546B2Efficient systemic treatment of dystrophic muscle pathologiesGENETHON·Filed 2018·Granted Sep 29, 2020·3 cites·6 claims
- 0587US11339406B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Granted May 24, 2022·3 cites·20 claims
- 0681US12351816B2CNS gene delivery using peripheral administration of AAV vectorsGENETHON·Filed 2023·Granted Jul 8, 2025·0 cites·8 claims
- 0780US2025333765A1Cns gene delivery using peripheral administration of aav vectorsGENETHON·Filed 2025·Application pending·0 cites
- 0879US10125352B2Method for producing enveloped virusesGENETHON·Filed 2014·Granted Nov 13, 2018·4 cites·7 claims
- 0977US12305187B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Granted May 20, 2025·0 cites·19 claims
- 1077US10465169B2Method for purifying enveloped viruses or viral vectorsGENETHON·Filed 2014·Granted Nov 5, 2019·4 cites·23 claims
- 1176US12037362B2Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropismGENETHON·Filed 2019·Granted Jul 16, 2024·1 cites·7 claims
- 1276US2025127930A1Hybrid regulatory elementsGENETHON·Filed 2024·Application pending·0 cites
- 1376US2024317814A1Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver TropismGENETHON·Filed 2024·Application pending·0 cites
- 1475US9862934B2Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virionsGENETHON·Filed 2015·Granted Jan 9, 2018·2 cites·8 claims
- 1575US2025270590A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2025·Application pending·0 cites
- 1673US10471132B2Treatment of hyperbilirubinemiaGENETHON·Filed 2015·Granted Nov 12, 2019·3 cites·19 claims
- 1772US11767538B2Widespread gene delivery to motor neurons using peripheral injection of AAV vectorsGENETHON·Filed 2019·Granted Sep 26, 2023·0 cites·13 claims
- 1871US11371061B2Compositions and methods for improving viral vector efficiencyGENETHON·Filed 2016·Granted Jun 28, 2022·2 cites·11 claims
- 1970US12023366B2Efficient systemic treatment of dystrophic muscle pathologiesGENETHON·Filed 2020·Granted Jul 2, 2024·0 cites·9 claims
- 2070US2024043867A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Application pending·0 cites
- 2169US11236307B2Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virionsGENETHON·Filed 2019·Granted Feb 1, 2022·0 cites·21 claims
- 2269US9981049B2Selective gene therapy expression systemGENETHON·Filed 2014·Granted May 29, 2018·1 cites·10 claims
- 2368US12582723B2Polynucleotides encoding a human FKRP proteinGENETHON·Filed 2023·Granted Mar 24, 2026·0 cites·9 claims
- 2467US2023414724A1Treatment of hyperbilirubinemiaGENETHON·Filed 2023·Application pending·0 cites
- 2567US2019153474A1Cns gene delivery using peripheral administration of aav vectorsGENETHON·Filed 2018·Application pending·0 cites
- 2666US9526742B2Use of epigenome-modifying compounds for the treatment of genetic muscular diseases linked to a protein-conformational disorderGENETHON·Filed 2013·Granted Dec 27, 2016·1 cites·2 claims
- 2766US2022235371A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2021·Application pending·0 cites
- 2865US2022389399A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Application pending·0 cites
- 2964US11819478B2Selective gene therapy expression systemGENETHON·Filed 2018·Granted Nov 21, 2023·0 cites·16 claims
- 3064US2026053923A1Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T CellsGENETHON·Filed 2023·Application pending·0 cites
- 3163US2023190965A1Treatment of glycogen storage disease iiiGENETHON·Filed 2022·Application pending·0 cites
- 3262US12171843B2Hybrid regulatory elementsGENETHON·Filed 2019·Granted Dec 24, 2024·0 cites·13 claims
- 3360US9933438B2Method for diagnosing muscular dystrophyGENETHON·Filed 2013·Granted Apr 3, 2018·1 cites·9 claims
- 3460US2019211360A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2019·Application pending·0 cites
- 3560US2021040503A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2020·Application pending·0 cites
- 3660US2022228167A1Peptide-Modified Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism and Increased Muscle TransductionGENETHON·Filed 2019·Application pending·0 cites
- 3760US2024350670A1Hybrid promoters for gene expression in muscles and in the cnsGENETHON·Filed 2022·Application pending·0 cites
- 3859US2023117384A1Compositions and methods for improving viral vector efficiencyGENETHON·Filed 2022·Application pending·0 cites
- 3958US10428315B2Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virionsGENETHON·Filed 2017·Granted Oct 1, 2019·0 cites·27 claims
- 4057US11993781B2Stable pseudotyped lentiviral particles and uses thereofGENETHON·Filed 2017·Granted May 28, 2024·0 cites·5 claims
- 4157US2024209030A1Peptide-Modified AAV CapsidGENETHON·Filed 2021·Application pending·0 cites
- 4256US11541131B2Treatment of glycogen storage disease IIIGENETHON·Filed 2018·Granted Jan 3, 2023·0 cites·21 claims
- 4356US10767192B2Baculovirus system for the expression of a gene therapy vectorGENETHON·Filed 2018·Granted Sep 8, 2020·0 cites·21 claims
- 4456US2023242905A1Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions SwappingGENETHON·Filed 2021·Application pending·0 cites
- 4556US2023250450A1NRF2 Activator for Use in Treating Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
- 4656US2023265427A1Treatment of Genetic Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
- 4756US2023220391A1CILP-1 Inhibitors for Use in the Treatment of Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
- 4855US2023203534A1Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapyGENETHON·Filed 2021·Application pending·0 cites
- 4954US2009220468A1Specific CD4+CD25+ Regulatory T Cells for Haematopoietic Cell Transplantation and Immune ToleranceGENETHON·Filed 2007·Application pending·0 cites
- 5053US2023277540A1Treatment of Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
Showing the top 50 of 86 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →